Skip to main content

Table 4 Proportion of AEs according to patients’ sex and genotype

From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

  TH BZB
  TH treatment TH AE % of pts with AE BZB treatment BZB AE % of pts with AE
male pts 41 25 61 23 6 26
female pts 26 12 46a 46 27 59b
ENG pts 17 17 100 10 2 20c
ACVRL1 pts 34 14 41 57 17 30d
  1. Comparing males to females : ap=0.32, b<0.01. Comparing thalidomide to bevacizumab, cp<0.001, d=0.36